1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 2, 15/Jan/2026
  4. Article
Research Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

BACKGROUND

Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RSV vaccines for adults ≥ 60 years were also available.

AIM

To report 2024 RSV epidemiology in Australia, identify risk factors for severe outcomes, and use and effectiveness of RSV immunisation products.

METHODS

National sentinel hospital-based RSV surveillance was established in 2024, recruiting hospitalised laboratory-confirmed RSV cases and test-negative controls from 22 sites in a national hospital network (FluCAN-PAEDS).

RESULTS

Between April and December 2024, 3,998 subjects (3,415 children; 582 adults) were hospitalised with RSV. Most cases were infants < 12 months (n = 1,534; 38.4%); 1,661 (41.5%) had underlying medical conditions. Children < 6 months, First Nations children, those born preterm or with underlying medical conditions (cardiac, neurological, genetic and metabolic disease/disorders, immunosuppression) were at greatest risk of severe outcomes. Severe outcomes were more frequent in adults with malignancy, respiratory or cardiac disease. Nirsevimab effectiveness against hospitalisation in infants < 12 months in the two Australian jurisdictions with population-wide immunisation programmes was 83.1% (95% CI: 67.4–91.3). RSV vaccine use (pregnancy; adults ≥ 60 years) was limited, precluding effectiveness assessments.

CONCLUSION

National surveillance enabled timely 2024 data collection with the capability to evaluate effectiveness of immunisation products preventing RSV. Nirsevimab demonstrated comparable effectiveness to that in the northern hemisphere, informing Australia’s 2025 strategy. Evaluation to assess the impact of more widespread uptake of RSV prevention products continues.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.2.2500275
2026-01-15
2026-02-08
/content/10.2807/1560-7917.ES.2026.31.2.2500275
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/2/eurosurv-31-2-5.html?itemId=/content/10.2807/1560-7917.ES.2026.31.2.2500275&mimeType=html&fmt=ahah

References

  1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55.  https://doi.org/10.1016/S0140-6736(10)60206-1  PMID: 20399493 
  2. Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S577-83.  https://doi.org/10.1093/infdis/jiz059  PMID: 30880339 
  3. Moore HC, Lim FJ, Fathima P, Barnes R, Smith DW, de Klerk N, et al. Assessing the Burden of Laboratory-Confirmed Respiratory Syncytial Virus Infection in a Population Cohort of Australian Children Through Record Linkage. J Infect Dis. 2020;222(1):92-101.  https://doi.org/10.1093/infdis/jiaa058  PMID: 32031631 
  4. Crawford NW, Alafaci A, Clark JE, Francis JR, Blyth CC, Pienaar C, et al. Study of Children Aged Under 2 Years Admitted With RSV at Four Australian Hospitals [2021-2022]. J Paediatr Child Health. 2025;61(3):482-90.  https://doi.org/10.1111/jpc.16769  PMID: 39825756 
  5. Sarna M, Blyth CC, Taye BW, Le H, Richmond P, Glass K, et al. Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years. Lancet Reg Health West Pac. 2025;61:101654.  https://doi.org/10.1016/j.lanwpc.2025.101654  PMID: 40822288 
  6. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook. Canberra: Australian Government. [Accessed: 8 Sep 2025]. Available from: https://immunisationhandbook.health.gov.au
  7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-59.  https://doi.org/10.1056/NEJMoa043951  PMID: 15858184 
  8. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64.  https://doi.org/10.1016/S0140-6736(22)00478-0  PMID: 35598608 
  9. Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021;73(9):e2829-30.  https://doi.org/10.1093/cid/ciaa1906  PMID: 33594407 
  10. Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis. 2021;72(12):2199-202.  https://doi.org/10.1093/cid/ciaa1475  PMID: 32986804 
  11. Commonwealth Department of Health and Aged Care. 2024 Annual Australian Respiratory Surveillance Report. Canberra: Australian Government. [Accessed: 8 Sep 2025]. Available from: https://www.health.gov.au/sites/default/files/2025-04/annual-australian-respiratory-surveillance-report-2024_0.pdf
  12. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-46.  https://doi.org/10.1056/NEJMoa2110275  PMID: 35235726 
  13. Zar HJ, Simoes E, Madhi S, Ramilo O, Senders S, Shepard JS, et al. 166. A phase 2b/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (rsv) antibody, clesrovimab, in healthy preterm and full-term infants. Open Forum Infect Dis. 2025;12(Supplement_1):ofae631.003.  https://doi.org/10.1093/ofid/ofae631.003 
  14. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent rsv illness in infants. N Engl J Med. 2023;388(16):1451-64.  https://doi.org/10.1056/NEJMoa2216480  PMID: 37018474 
  15. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595-608.  https://doi.org/10.1056/NEJMoa2209604  PMID: 36791160 
  16. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465-77.  https://doi.org/10.1056/NEJMoa2213836  PMID: 37018468 
  17. Kelly PM, Kotsimbos T, Reynolds A, Wood-Baker R, Hancox B, Brown SG, et al. FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. Med J Aust. 2011;194(4):169-74.  https://doi.org/10.5694/j.1326-5377.2011.tb03764.x  PMID: 21401456 
  18. McRae JE, Quinn HE, Saravanos GL, Carlson SJ, Britton PN, Crawford NW, et al. Paediatric Active Enhanced Disease Surveillance (PAEDS) 2017 and 2018: Prospective hospital-based surveillance for serious paediatric conditions. Commun Dis Intell. 2018;2020:44.
  19. Commonwealth Department of Health and Aged Care. Australian National Surveillance Plan for COVID-19, Influenza and RSV. Canberra: Australian Government. [Accessed: 8 Sep 2025]. Available from: https://www.health.gov.au/sites/default/files/2024-04/australian-national-surveillance-plan-for-covid-19-influenza-and-rsv_1.pdf
  20. Foley DA, Minney-Smith CA, Tjea A, Nicol MP, Levy A, Moore HC, et al. The changing detection rate of respiratory syncytial virus in adults in Western Australia between 2017 and 2023. Viruses. 2024;16(5):656.  https://doi.org/10.3390/v16050656  PMID: 38793538 
  21. Bloomfield LE, Pingault N, Foong R, French S, Morgan JA, Wadia U, et al. Impact of nirsevimab on RSV-associated hospitalisations among infants in WA in 2024. Med J Aust. 2025. Forthcoming.
  22. Commonwealth Department of Health. Disability and Aging. PBAC Meeting Outcomes - July: 2025. Hearing before the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government; 2025. Available from: https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-07/pbac-web-outcomes-07-2025.pdf
  23. Pérez Marc G, Vizzotti C, Fell DB, Di Nunzio L, Olszevicki S, Mankiewicz SW, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect Dis. 2025;25(9):1044-54.  https://doi.org/10.1016/S1473-3099(25)00156-2  PMID: 40339585 
  24. Williams TC, Marlow R, Cunningham S, Drysdale SB, Groves HE, Hunt S, et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. Lancet Child Adolesc Health. 2025;9(9):655-62.  https://doi.org/10.1016/S2352-4642(25)00155-5  PMID: 40690922 
  25. Carbajal R, Boelle PY, Pham A, Chazette Y, Schellenberger M, Weil C, et al. Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France. Lancet Child Adolesc Health. 2024;8(10):730-9.  https://doi.org/10.1016/S2352-4642(24)00171-8  PMID: 39208832 
  26. Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29(4):2400033.  https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033  PMID: 38275017 
  27. López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):2400046.  https://doi.org/10.2807/1560-7917.ES.2024.29.6.2400046  PMID: 38333937 
  28. Torres JP, Sauré D, Goic M, Thraves C, Pacheco J, Burgos J, et al. Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study. Lancet Infect Dis. 2025;25(11):1189-98.  https://doi.org/10.1016/S1473-3099(25)00233-6  PMID: 40513593 
  29. Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-22.  https://doi.org/10.15585/mmwr.mm7241e1  PMID: 37824423 
  30. Commonwealth Department of Health and Aged Care. Australian hospital statistics public hospitals. Canberra: Australian Government. [Accessed: 8 Sep 2025]. Available from: https://data.gov.au/data/dataset/australian-hospital-statistics-public-hospitals
Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS)
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Christopher+C+Blyth&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Blyth Christopher C</a>, <a href="/search?value1=Ushma+Wadia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wadia Ushma</a>, <a href="/search?value1=Philip+N+Britton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Britton Philip N</a>, <a href="/search?value1=Jeremy+Carr&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Carr Jeremy</a>, <a href="/search?value1=Julia+E+Clark&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Clark Julia E</a>, <a href="/search?value1=Nigel+W+Crawford&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Crawford Nigel W</a>, <a href="/search?value1=Te-Yu+Hung&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hung Te-Yu</a>, <a href="/search?value1=Kristine+K+Macartney&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Macartney Kristine K</a>, <a href="/search?value1=Helen+S+Marshall&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Marshall Helen S</a>, <a href="/search?value1=Nicholas+J+Wood&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wood Nicholas J</a>, <a href="/search?value1=Tom+Kotsimbos&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kotsimbos Tom</a>, <a href="/search?value1=Paul+M+Kelly&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kelly Paul M</a>, <a href="/search?value1=Allen+C+Cheng&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cheng Allen C</a>, <a href="/search?value1=FluCAN-PAEDS+network&option1=author&noRedirect=true" class="nonDisambigAuthorLink">FluCAN-PAEDS network</a></span>. Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS). <a href="/content/ecdc">Euro Surveill.</a> 2026;31(2):pii=2500275. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500275" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500275</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 16 Apr 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 01 Oct 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.2.2500275
/content/10.2807/1560-7917.ES.2026.31.2.2500275
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error